AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy

AAV genome loss from dystrophic mouse muscles during AAV-U7 snRNA-mediated exon-skipping therapy

In the context of future adeno-associated viral (AAV)-based clinical trials for Duchenne myopathy, AAV genome fate in dystrophic muscles is of importance considering the viral capsid immunogenicity that prohibits recurring treatments. We showed that AAV genomes encoding non-therapeutic U7 were lost...

書誌詳細
主要な著者:	Le Hir, M, Goyenvalle, A, Peccate, C, Précigout, G, Davies, K, Voit, T, Garcia, L, Lorain, S
フォーマット:	Journal article
言語:	English
出版事項:	2013

類似資料

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
著者:: Goyenvalle, A, 等
出版事項: (2010)

AAV-U7snRNA mediated multi exon-skipping for Duchenne muscular dystrophy
著者:: Goyenvalle, A, 等
出版事項: (2011)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping
著者:: Goyenvalle, A, 等
出版事項: (2012)

Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.
著者:: Goyenvalle, A, 等
出版事項: (2012)

Long-Term Efficacy of AAV9-U7snRNA-Mediated Exon 51 Skipping in mdx52 Mice
著者:: Philippine Aupy, 等
出版事項: (2020-06-01)

Upgrading U7snRNA To Complete Efficient Rescue of Dystrophin by Exon-Skipping in DMD Patients
著者:: Goyenvalle, A, 等
出版事項: (2009)

Engineering exon-skipping vectors expressing U7 snRNA constructs for Duchenne muscular dystrophy gene therapy.
著者:: Goyenvalle, A, 等
出版事項: (2011)

Rescue of cardiomyopathy through U7snRNA‐mediated exon skipping in Mybpc3‐targeted knock‐in mice
著者:: Christina Gedicke‐Hornung, 等
出版事項: (2013-05-01)

Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy.
著者:: Goyenvalle, A, 等
出版事項: (2009)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy
著者:: Goyenvalle, A, 等
出版事項: (2012)

Engineering multiple U7snRNA constructs to induce single and multiexon-skipping for Duchenne muscular dystrophy.
著者:: Goyenvalle, A, 等
出版事項: (2012)

Rescue of common and rare exon 2 skipping variants of the GAA gene using modified U1 snRNA
著者:: Paolo Peruzzo, 等
出版事項: (2025-02-01)

Use of antisense-mediated exon skipping to generate dystrophin in muscles of the mdx dystrophic mouse
著者:: Lu, Q, 等
出版事項: (2004)

Persistence of exon 2 skipping and dystrophin expression at 18 months after U7snRNA-mediated therapy in the Dup2 mouse model
著者:: Liubov V. Gushchina, 等
出版事項: (2023-12-01)

Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping.
著者:: Goyenvalle, A, 等
出版事項: (2010)

Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
著者:: Lu, Q, 等
出版事項: (2003)

Pre-clinical dose-escalation studies establish a therapeutic range for U7snRNA-mediated DMD exon 2 skipping
著者:: Tabatha R. Simmons, 等
出版事項: (2021-06-01)

Exon exchange approach to repair Duchenne dystrophin transcripts.
著者:: Stéphanie Lorain, 等
出版事項: (2010-01-01)

Systemic delivery of an AAV9 exon-skipping vector significantly improves or prevents features of Duchenne muscular dystrophy in the Dup2 mouse
著者:: Nicolas Wein, 等
出版事項: (2022-09-01)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.
著者:: Eckenfelder, A, 等
出版事項: (2012)

The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery
著者:: Agathe Eckenfelder, 等
出版事項: (2012-01-01)

Combined treatment with peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) and AAV-U7 rescues the severe DMD phenotype in mice
著者:: Forand, A, 等
出版事項: (2020)

Combined Treatment with Peptide-Conjugated Phosphorodiamidate Morpholino Oligomer-PPMO and AAV-U7 Rescues the Severe DMD Phenotype in Mice
著者:: Anne Forand, 等
出版事項: (2020-06-01)

Exon Skipping in a Dysf-Missense Mutant Mouse Model
著者:: Jakub Malcher, 等
出版事項: (2018-12-01)

Nab Escaping AAV Mutants Isolated from Mouse Muscles
著者:: Zheng Chai, 等
出版事項: (2018-05-01)

AAV genome modification for efficient AAV production
著者:: Walaa Asaad, 等
出版事項: (2023-04-01)

U1 snRNA interactions with deep intronic sequences regulate splicing of multiple exons of spinal muscular atrophy genes
著者:: Eric W. Ottesen, 等
出版事項: (2024-07-01)

A single m6A modification in U6 snRNA diversifies exon sequence at the 5’ splice site
著者:: Yuma Ishigami, 等
出版事項: (2021-05-01)

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.
著者:: Aoki, Y, 等
出版事項: (2012)

Highly efficient CRISPR/Cas9‐mediated exon skipping for recessive dystrophic epidermolysis bullosa
著者:: Alex du Rand, 等
出版事項: (2024-07-01)

T Cell-Mediated Immune Responses to AAV and AAV Vectors
著者:: Hildegund C. J. Ertl
出版事項: (2021-04-01)

Rational Design of AAV-rh74, AAV3B, and AAV8 with Limited Liver Targeting
著者:: Christopher Chan, 等
出版事項: (2023-10-01)

Investigating the Impact of Delivery Routes for Exon Skipping Therapies in the CNS of DMD Mouse Models
著者:: Amel Saoudi, 等
出版事項: (2023-03-01)

Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
著者:: Yokota, T, 等
出版事項: (2012)

Antisense Oligonucleotide-mediated Exon Skipping as a Systemic Therapeutic Approach for Recessive Dystrophic Epidermolysis Bullosa
著者:: Jeroen Bremer, 等
出版事項: (2016-01-01)

U1 snRNA associates with TFIIH and regulates transcriptional initiation.
著者:: Kwek, K, 等
出版事項: (2002)

Mechanism of U6 snRNA oligouridylation by human TUT1
著者:: Seisuke Yamashita, 等
出版事項: (2023-08-01)

Crystal structures of U6 snRNA-specific terminal uridylyltransferase
著者:: Seisuke Yamashita, 等
出版事項: (2017-06-01)

Rescu of severely affected dystrophin/utrophin deficient mice by morpholino-oligomer mediated exon skipping
著者:: Goyenvalle, A, 等
出版事項: (2010)

AAV2 and AAV9 tropism and transgene expression in the mouse eye and major tissues after intravitreal and subretinal delivery
著者:: Sanna Koponen, 等
出版事項: (2023-07-01)